Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
The latest news, research, and perspectives in chronic lymphocytic leukemia (CLL). The most common leukemia subtype among adults, CLL occurs when an acquired mutation causes bone marrow to produce abnormal lymphocytes. As these leukemic cells proliferate, the disorder is associated with lymphadenopathy, splenomegaly, and cytopenias.
Advertisement
Melissa BadamoChronic Lymphocytic Leukemia | June 20, 2024
More patients with CLL receiving acalabrutinib acquired BTK mutations than those receiving ibrutinib, but did not fare worse.
Read More
Andrew MorenoChronic Lymphocytic Leukemia | June 20, 2024
The regimen even produced benefit in CLL patients who had already been treated with a covalent BTKi.
Patrick DalyChronic Lymphocytic Leukemia | June 20, 2024
Venetoclax and obinutuzumab with or without ibrutinib improved PFS versus chemoimmunotherapy or venetoclax and rituximab.
Melissa BadamoChronic Lymphocytic Leukemia | June 12, 2024
The incidence of bleeding events in patients with CLL receiving BTKis is 26.6 per 100 patients per year.
Mazyar Shadman, MD, MPHChronic Lymphocytic Leukemia | June 12, 2024
The study utilized three clinical trials to compare the efficacy of acalabrutinib, zanubrutinib, and ibrutinib for CLL.
Fateeha Furqan, MDChronic Lymphocytic Leukemia | June 10, 2024
Dr. Furqan shared data from a retrospective analysis on patients who received pirtobrutinib prior to CAR T-cell therapy.
Advertisement
Melissa BadamoChronic Lymphocytic Leukemia | May 29, 2024
Liso-cel was approved in March 2024 by the FDA for patients with relapsed or refractory CLL.
Elias Jabbour, MDPrint | May 22, 2024
In this executive editor's message, Elias Jabbour, MD, writes about redefining leukemias as curable or less curable.
Leah LawrenceChronic Lymphocytic Leukemia | May 17, 2024
A new evaluation of the CLL-IPI revealed that its impact appears diminished in predicting OS in the era of targeted drugs.
Leah LawrenceChronic Lymphocytic Leukemia | May 17, 2024
The ELCLV3-21  high-risk signature distinguished those with MBL with a high probability of progression.
Leah LawrenceChronic Lymphocytic Leukemia | May 17, 2024
Using data from CLL long-term cultures, the researchers found that TBX21 expression was induced in CLL cells.
Chadi Nabhan, MD, MBA, FACPChronic Lymphocytic Leukemia | May 30, 2024
Dr. Hilal covers the debates surrounding MRD, whether he uses MRD to make treatment decisions, and more.
Patrick DalyChronic Lymphocytic Leukemia | April 19, 2024
Loss of inhibitor of kappa B epsilon was found to drive NF-κB pathway activity and migration and proliferation of CLL cells.
Patrick DalyChronic Lymphocytic Leukemia | April 19, 2024
CAR T-cell therapies effectively treated patients with Richter transformation, an aggressive subtype of CLL.
Patrick DalyChronic Lymphocytic Leukemia | April 19, 2024
Patients with Richter transformation had improved outcomes when treated with venetoclax-based treatment regimens.
Catherine Coombs, MDChronic Lymphocytic Leukemia | April 19, 2024
Catherine Coombs, MD, outlined some of her research into the solid tumor microenvironment, particularly in prostate cancer.
Paolo Ghia, MD, PhDChronic Lymphocytic Leukemia | April 9, 2024
Paolo Ghia, MD, PhD talks about his session on monoclonal B-cell lymphocytosis presented at the AACR Annual Meeting 2024.
Elias Jabbour, MDChronic Lymphocytic Leukemia | March 29, 2024
Elias Jabbour, MD, discusses the latest news and novel therapies in CLL.
Melissa BadamoChronic Lymphocytic Leukemia | March 29, 2024
In patients with CLL, zanubrutinib showed advantages in PFS and CR rates with "potentially improved" OS.
Tanya Siddiqi, MDChronic Lymphocytic Leukemia | March 29, 2024
Dr. Siddiqi shares data from the phase I/II TRANSCEND CLL 004 trial on liso-cel in patients with relapsed or refractory CLL.
Advertisement
Advertisement
Editorial Board